{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:47:02Z","timestamp":1784544422517,"version":"3.55.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review aims to assess the current state of bone and soft tissue sarcomas (STS) management in the adolescent and young adult population (AYA) with a focus on Ewing sarcoma (EWS), osteosarcoma (OS), rhabdomyosarcoma (RMS), and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>There has been a significant growth in novel agents available for bone sarcomas in the AYA population; trials continue to study the efficacy of these agents. The future of STS will likely include more single histology and targeted biologic studies. Joint pediatric and adult sarcoma clinical trials are feasible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>AYAs continue to represent an underserved patient population in medical oncology. Collaboration between pediatric and adult practices may increase patient enrollment and enable single histology and biology specific studies. Trials for EWS, OS, RMS, and NRSTS should include both pediatric and adult patients whenever possible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-026-01781-8","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:51:21Z","timestamp":1779267081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sarcomas in Adolescents and Young Adults"],"prefix":"10.1007","volume":"28","author":[{"given":"Jacob R.","family":"Greenmyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Allen-Rhoades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"1781_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70113-5","volume":"15","author":"LA Fern","year":"2014","unstructured":"Fern LA, Lewandowski JA, Coxon KM, et al. Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials. Lancet Oncol. 2014;15:e341-350.","journal-title":"Lancet Oncol"},{"key":"1781_CR2","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1781_CR3","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1002\/cncr.24388","volume":"115","author":"MU Jaward","year":"2009","unstructured":"Jaward MU, Cheung MC, Min ES, et al. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973\u20132005. Cancer. 2009;115:3526\u201336.","journal-title":"Cancer"},{"key":"1781_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/gim.2016.206","volume":"19","author":"AS Brohl","year":"2017","unstructured":"Brohl AS, Patidar R, Turner CE, et al. Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. Genet Med. 2017;19:955\u20138.","journal-title":"Genet Med"},{"issue":"2","key":"1781_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ng0294-146","volume":"6","author":"PH Sorensen","year":"1994","unstructured":"Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing\u2019s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994;6(2):146\u201351.","journal-title":"Nat Genet"},{"key":"1781_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.suronc.2018.07.016","volume":"27","author":"SE Bosma","year":"2018","unstructured":"Bosma SE, Ayu O, Fiocco M, et al. Prognostic factors for survival in Ewing sarcoma: a systematic review. Surgical Oncology. 2018;27:603\u201310.","journal-title":"Surgical Oncology"},{"issue":"30","key":"1781_CR7","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1200\/JCO.23.00053","volume":"41","author":"T Cash","year":"2023","unstructured":"Cash T, Krailo MD, Buxton A, et al. Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy on Children\u2019s Oncology Group study AEWS0031. J Clin Oncol. 2023;41(30):4724\u20138.","journal-title":"J Clin Oncol"},{"key":"1781_CR8","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.21.00358","volume":"39","author":"PJ Leavey","year":"2021","unstructured":"Leavey PJ, Laack NN, Krailo MD, et al. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients with Nonmetastatic Ewing Sarcoma: A Children\u2019s Oncology Group Report. J Clin Oncol. 2021;39:4029\u201338.","journal-title":"J Clin Oncol"},{"key":"1781_CR9","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1200\/JCO.1990.8.10.1664","volume":"8","author":"ME Nesbit Jr","year":"1990","unstructured":"Nesbit ME Jr, Gehan EA. Multimodal therapy for the management of primary, nonmetastatic Ewing\u2019s sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol. 1990;8:1514\u201324.","journal-title":"J Clin Oncol"},{"key":"1781_CR10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa020890","volume":"348","author":"HE Grier","year":"2003","unstructured":"Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694\u2013701.","journal-title":"N Engl J Med"},{"key":"1781_CR11","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1200\/JCO.2008.16.5720","volume":"26","author":"M Paulussen","year":"2008","unstructured":"Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing\u2019s sarcoma treatment\u2014cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit added to standard treatment in high-risk patients. J Clin Oncol. 2008;26:4385\u201393.","journal-title":"J Clin Oncol"},{"key":"1781_CR12","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1200\/JCO.2013.54.4833","volume":"32","author":"MC Le Deley","year":"2014","unstructured":"Le Deley MC, Paaulussen M, Lewis I, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EwingG99-R1 trial. J Clin Oncol. 2014;32:2440\u20138.","journal-title":"J Clin Oncol"},{"key":"1781_CR13","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","volume":"30","author":"RB Womer","year":"2012","unstructured":"Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30:4148\u201354.","journal-title":"J Clin Oncol"},{"key":"1781_CR14","doi-asserted-by":"publisher","first-page":"11500","DOI":"10.1200\/JCO.2020.38.15_suppl.11500","volume":"38","author":"B Brennan","year":"2020","unstructured":"Brennan B, Kirton L, Marec-Berard P, et al. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). J Clin Oncol. 2020;38:11500.","journal-title":"J Clin Oncol"},{"key":"1781_CR15","unstructured":"Whelan J, Le Deley MC, Dirksen U et al. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk ewing sarcoma: results of the EURO-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018:JCO20187882516."},{"key":"1781_CR16","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.19.00915","volume":"37","author":"U Dirksen","year":"2019","unstructured":"Dirksen U, Brennan B, Le Deley MC, et al. Hgh-Dose chemotherapy compared with standard chemotherpay and radiation in Ewing sarcoma with pulmonary metastases: Results of the European Ewing Tumor Working Initiative of National Groups, 99 Trial and Ewing 2008. J Clin Oncol. 2019;37:3192\u2013202.","journal-title":"J Clin Oncol"},{"key":"1781_CR17","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1002\/cncr.34942","volume":"129","author":"A Gupta","year":"2023","unstructured":"Gupta A, Riedel R, Shah C, et al. Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board. Cancer. 2023;129:3363\u201371.","journal-title":"Cancer"},{"issue":"11","key":"1781_CR18","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.22.01815","volume":"41","author":"SG DuBois","year":"2023","unstructured":"DuBois SG, Krailo MD, Glade-Bender J, et al. Randomized Phase III Trial of Ganitumab with Interval-Compressed Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children\u2019s Oncology Group. J Clin Oncol. 2023;41(11):2098\u2013107. https:\/\/doi.org\/10.1200\/JCO.22.01815.","journal-title":"J Clin Oncol"},{"key":"1781_CR19","unstructured":"National Comprehensive Cancer Network. Bone Cancer (Version 2025.09.11). NCCN Clinical Practice Guidelines in Oncology. Published September 11, 2025."},{"key":"1781_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2016.03.075","volume":"61","author":"S Foulon","year":"2016","unstructured":"Foulon S, Brenna B, Gaspar N, et al. Can postoperative radiotherapy be omitted in localized standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G. group. Eur J Cancer. 2016;61:128\u201336.","journal-title":"Eur J Cancer"},{"key":"1781_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.radonc.2014.11.023","volume":"113","author":"PA Casey Dl, Meyers","year":"2014","unstructured":"Casey Dl, Meyers PA, Alektiar KM, et al. Ewing sarcoma in adults treated with modern radiotherapy techniques. Radiother Oncol. 2014;113:248\u201353.","journal-title":"Radiother Oncol"},{"issue":"2","key":"1781_CR22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ijrobp.2023.09.007","volume":"118","author":"L Chang","year":"2024","unstructured":"Chang L, D\u2019Amiano A, Bhatia R, et al. Impact of Consolidative Radiation on Overall and Progression-Free Survival in Pediatric, Adolescent, and Young Adult Metastatic Bone and Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys. 2024;118(2):474\u201384.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1781_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1023\/A:1008208511815","volume":"9","author":"M Paulussen","year":"1998","unstructured":"Paulussen M, Ahrens S, Burdach S, et al. Primary Metastatic (Stage IV) Ewing Tumor: Survivor Analysis of 171 Patients from the EICESS Studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998;9(3):275\u201381.","journal-title":"Ann Oncol"},{"issue":"19","key":"1781_CR24","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/JCO.2005.05.105","volume":"23","author":"LM Barker","year":"2005","unstructured":"Barker LM, Pandergrass TW, Sanders JE, et al. Survival after recurrence of Ewing\u2019s sarcoma family of tumors. J Clin Oncol. 2005;23(19):4354\u201362.","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"1781_CR25","doi-asserted-by":"publisher","first-page":"11007","DOI":"10.1200\/JCO.2019\/37.15_suppl.11007","volume":"37","author":"MG McCabe","year":"2019","unstructured":"McCabe MG, Moroz V, Khan M, et al. Results of the first interim assessment of rEECur, and international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma [abstract]. J Clin Oncol. 2019;37(15 suppl):11007. https:\/\/doi.org\/10.1200\/JCO.2019\/37.15_suppl.11007.","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"1781_CR26","doi-asserted-by":"publisher","first-page":"11502","DOI":"10.1200\/JCO.2020.38.15_suppl.11502","volume":"38","author":"MG McCabe","year":"2020","unstructured":"McCabe MG, Kirton L, Khan M, et al. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractoryEwing sarcoma (RR-ES) [abstract]. J Clin Oncol. 2020;38(15 suppl):11502. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.11502.","journal-title":"J Clin Oncol"},{"issue":"17 suppl","key":"1781_CR27","doi-asserted-by":"publisher","first-page":"LBA2","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA2","volume":"40","author":"M McCabe","year":"2022","unstructured":"McCabe M, Kirton L, Khan M, et al. Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RRES) [abstract]. J Clin Oncol. 2022;40(17 suppl):LBA2. https:\/\/doi.org\/10.1200\/JCO.2022.40.17_suppl.LBA2.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1781_CR28","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1158\/1078-0432.CCR-22-3546","volume":"29","author":"J Xu","year":"2023","unstructured":"Xu J, Xie L, Sun X, et al. Longer versus shorter schedules of vincristine, irinotecan, and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controleld phase 2 trial. Clin Cancer Res. 2023;29(6):1040\u20136. https:\/\/doi.org\/10.1158\/1078-0432.Ccr\u201022\u20103546.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1781_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30005","volume":"70","author":"EK Slotkin","year":"2023","unstructured":"Slotkin EK, Meyers PA. Irinotecan dose schedule for treatment the treatment of Ewing sarcoma. Pediatr Blood Cancer. 2023;70(1):e30005. https:\/\/doi.org\/10.1002\/pbc.30005.","journal-title":"Pediatr Blood Cancer"},{"issue":"16 suppl","key":"1781_CR30","doi-asserted-by":"publisher","first-page":"TPS10073","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS10073","volume":"41","author":"JA Bacha","year":"2023","unstructured":"Bacha JA, Brown D, Geller JI, et al. A pilot clinical study of oral irinotecan HCL (VAL-413) in patients with recurrent pediatric solid tumors [abstract]. J Clin Oncol. 2023;41(16 suppl):TPS10073. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS10073.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1781_CR31","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/jco.21.02838","volume":"40","author":"DW Parsons","year":"2022","unstructured":"Parsons DW, Janeway KA, Patton DR, et al. Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the National Cancer Institute-Children\u2019s Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022;40(20):2224\u201334. https:\/\/doi.org\/10.1200\/jco.21.02838.","journal-title":"J Clin Oncol"},{"key":"1781_CR32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/1471-2407-14-813","volume":"14","author":"E Choy","year":"2014","unstructured":"Choy E, Butrynski JE, Harmon DC, et al. Phase II study of Olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014;14:813.","journal-title":"BMC Cancer"},{"issue":"8","key":"1781_CR33","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/cncr.33349","volume":"127","author":"R Chugh","year":"2021","unstructured":"Chugh R, Ballman KV, Helman LJ, et al. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer. 2021;127(8):1301\u201310.","journal-title":"Cancer"},{"issue":"12","key":"1781_CR34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41416-023-02413-9","volume":"129","author":"F Duffaud","year":"2023","unstructured":"Duffaud F, Blay JY, Le Cesne A, et al. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomized, double-blind, placebo-controlled, multicentre Phase II study. Br J Cancer. 2023;129(12):194\u20131948.","journal-title":"Br J Cancer"},{"key":"1781_CR35","doi-asserted-by":"crossref","unstructured":"Ludwig JA, Federman NC, Anderson PM et al. TK216 for relapsed\/refractory Ewing sarcoma: Interm phase I\/II results. Journal of Clinic Oncology. 2021;39(15). Presented at 2021 ASCO Annual Meeting.","DOI":"10.1200\/JCO.2021.39.15_suppl.11500"},{"issue":"31","key":"1781_CR36","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1200\/JCO.24.00020","volume":"42","author":"PA Meyers","year":"2024","unstructured":"Meyers PA, Federman N, Daw N, et al. Open-Label, Multicenter, Phase I\/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonists in Ewing Sarcoma. J Clin Oncol. 2024;42(31):3725\u201334.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1781_CR37","doi-asserted-by":"publisher","first-page":"15207","DOI":"10.1002\/cam4.6208","volume":"12","author":"DS Shulman","year":"2023","unstructured":"Shulman DS, Merriam P, Choy E, et al. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med. 2023;12(14):15207\u201316.","journal-title":"Cancer Med"},{"key":"1781_CR38","doi-asserted-by":"crossref","unstructured":"Subbiah, Brana I, Longhi A et al. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II study. Clin Cancer Res. 2022;28(13):2762\u20132770.","DOI":"10.1158\/1078-0432.CCR-22-0696"},{"issue":"16","key":"1781_CR39","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1200\/JCO.18.02374","volume":"37","author":"LE Davis","year":"2019","unstructured":"Davis LE, Bolejack V, Ryan CW, et al. Randomized Double-Blind Phase II Study of Regorafenib in Patients with Metastatic Osteosarcoma. J Clin Oncol. 2019;37(16):1424\u201331.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1781_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","volume":"20","author":"F Duffaud","year":"2019","unstructured":"Duffaud F, Mir O, Boudou-Rouquette, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative randomized, double-blind, placebo-controlled phase 2 study. Lancet Oncol. 2019;20(1):120\u201333.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1781_CR41","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jamaoncol.2024.4381","volume":"10","author":"N Gaspar","year":"2024","unstructured":"Gaspar N, Hung GY, Strauss SJ, et al. Levatinib Plus Ifosfamide and Etoposide in Chidlren and Young Adults with Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2024;10(12):1645\u201353.","journal-title":"JAMA Oncol"},{"key":"1781_CR42","doi-asserted-by":"crossref","unstructured":"Tang Q, Zhang X, Zhu X et al. Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial. Cancer Med;13:e70206.","DOI":"10.1002\/cam4.70206"},{"issue":"7","key":"1781_CR43","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1634\/theoncologist.2018-0542","volume":"24","author":"L Xie","year":"2019","unstructured":"Xie L, Xu J, Sun X, et al. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An open Label Phase II Clinical Trial. Oncologist. 2019;24(7):e542\u201350.","journal-title":"Oncologist"},{"key":"1781_CR44","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","volume":"137","author":"SM Federico","year":"2020","unstructured":"Federico SM, Pappo AS, Sahr N, et al. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer. 2020;137:204\u201313.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1781_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","volume":"21","author":"A Italiano","year":"2020","unstructured":"Italiano A, Mir O, Mathoulin-Pelissier SM, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):446\u201355.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1781_CR46","doi-asserted-by":"publisher","first-page":"e35628","DOI":"10.1002\/cncr.35628","volume":"131","author":"E Palmerini","year":"2025","unstructured":"Palmerini E, Pousa AL, Grignani G, et al. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. Cancer. 2025;131(1):e35628.","journal-title":"Cancer"},{"issue":"2","key":"1781_CR47","doi-asserted-by":"publisher","first-page":"e28073","DOI":"10.1002\/pbc.28073","volume":"67","author":"ES Schafer","year":"2020","unstructured":"Schafer ES, Rau RE, Berg SL, et al. Phase I\/II trial of talazoparib in combination with temozolomide in children and adolescents with refractory\/recurrent solid tumors including Ewing sarcoma: A Children\u2019s Oncology Group Phase 1 Consoritum Study (ADVL141). Pediatr Blood Cancer. 2020;67(2):e28073.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12885-020-6683-0","volume":"20","author":"PN Amadeo","year":"2020","unstructured":"Amadeo PN, Coindre JM, et al. Incidence and time trends of sarcoma (2000\u20132013): results from the French network of cancer registries (RANCIM). BMC Cancer. 2020;20:190.","journal-title":"BMC Cancer"},{"key":"1781_CR49","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamaoncol.2020.0197","volume":"6","author":"L Mirabello","year":"2020","unstructured":"Mirabello L, Zhu B, Koster R, et al. Frequency of pathogenic germline variants in cancer-susceptability genes in patients with osteosarcoma. JAMA Oncology. 2020;6:724\u201334.","journal-title":"JAMA Oncology"},{"key":"1781_CR50","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/PAP.0000000000000190","volume":"25","author":"M Hameed","year":"2018","unstructured":"Hameed M, Mandelker D. Tumor syndromes predisposing to osteosarcoma. Adv Anat Pathol. 2018;25:217\u201322.","journal-title":"Adv Anat Pathol"},{"key":"1781_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"HC Beird","year":"2022","unstructured":"Beird HC, Bielack S, Flanagan AM, et al. Osteosarcoma Nat Reviews Disease Primers. 2022;8:77.","journal-title":"Osteosarcoma Nat Reviews Disease Primers"},{"key":"1781_CR52","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/annonc\/mdn723","volume":"20","author":"MS Kim","year":"2009","unstructured":"Kim MS, Lee SY, Lee TR, et al. Prognostic nomogram for predicting the 5-year probabilyt of developing metastasis after neo-adjvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol. 2009;20:955\u201360.","journal-title":"Ann Oncol"},{"key":"1781_CR53","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","volume":"17","author":"NM Marina","year":"2016","unstructured":"Marina NM, Smeland S, Bielack SS, et al. Comaprison of MAPIE vs MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17:1396\u2013408.","journal-title":"Lancet Oncol"},{"key":"1781_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","volume":"109","author":"S Smeland","year":"2019","unstructured":"Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36\u201350.","journal-title":"Eur J Cancer"},{"key":"1781_CR55","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/pbc.25753","volume":"63","author":"CL Schwartz","year":"2016","unstructured":"Schwartz CL, Wexler LH, Krailo MD, et al. Intensified chemotherapy with dexrazoxane cardioprotection in newly metastatic osteosarcoma: a report from the children\u2019s oncology group. Pediatr Blood Cancer. 2016;63:54\u201361.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR56","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2008.16.2305","volume":"27","author":"SS Bielack","year":"2009","unstructured":"Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009;27:557\u201365.","journal-title":"J Clin Oncol"},{"key":"1781_CR57","doi-asserted-by":"publisher","first-page":"e27792","DOI":"10.1002\/pbc.27792","volume":"66","author":"E Palmerini","year":"2019","unstructured":"Palmerini E, Torricelli E, Cascinu S, et al. Is there a role for cheomtherapy after local relapse in high-grade osteosarcoma? Pediatr Blood Cancer. 2019;66:e27792.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR58","doi-asserted-by":"publisher","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali PG, Bielack S, Abecassis N, et al. Bone sardomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv79\u201395.","journal-title":"Ann Oncol"},{"key":"1781_CR59","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/pbc.23252","volume":"57","author":"A Ferrari","year":"2011","unstructured":"Ferrari A, Sultan I, Huang TT, et al. Soft tissue sarcoma across the age spectrum: A population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer. 2011;57:943\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR60","unstructured":"Bleyer A, O\u2019Leary M, Barr R et al. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 19 Years of Age, Including SEER Incidence and Survival: 1975\u20132000. Bethesda, MD, National Cancer Instititue, NIH publication number 06-5767. 2006."},{"key":"1781_CR61","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cncr.10669","volume":"95","author":"DJ Little","year":"2002","unstructured":"Little DJ, Ballo MT, Zagars GK, et al. Adult rhabdomyosarcoma: Outcome following multimodality treatment. Cancer. 2002;95:377\u201388.","journal-title":"Cancer"},{"key":"1781_CR62","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/JCO.2001.19.12.3091","volume":"19","author":"WM Crist","year":"2001","unstructured":"Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091\u2013102.","journal-title":"J Clin Oncol"},{"key":"1781_CR63","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1200\/JCO.20.03060","volume":"39","author":"JF Shern","year":"2021","unstructured":"Shern JF, Selfe J, Izquierdo E, et al. Genomic classification and clinical outcome in rhabdomyosarcoma: A report from an International Consortium. J Clin Oncol. 2021;39:2859\u201371.","journal-title":"J Clin Oncol"},{"key":"1781_CR64","doi-asserted-by":"publisher","first-page":"953","DOI":"10.5858\/arpa.2021-0183-RA","volume":"146","author":"R Fan","year":"2022","unstructured":"Fan R, Parham DM, Wang LL. An integrative morphologic and molecular approach for diagnosis and subclassification of rhabdomyosarcoma. Arch Pathol Lab Med. 2022;146:953\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"1781_CR65","doi-asserted-by":"publisher","first-page":"e29644","DOI":"10.1002\/pbc.29644","volume":"69","author":"JN Crane","year":"2022","unstructured":"Crane JN, Xue W, Qumseya A, et al. Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2022;69:e29644.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR66","unstructured":"Han D, Li C, Li X et al. Prognostic factors in patietns with rhabdomyosarcoma using competing-risks analysis: A study of cases in the SEER database. J Oncol. 2022;2635486."},{"key":"1781_CR67","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1002\/cam4.2504","volume":"8","author":"E Hibbits","year":"2019","unstructured":"Hibbits E, Chi YY, Hawkins DS, et al. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children\u2019s Oncology Group. Cancer Med. 2019;8:6437\u201348.","journal-title":"Cancer Med"},{"key":"1781_CR68","doi-asserted-by":"publisher","first-page":"e29511","DOI":"10.1002\/pbc.29511","volume":"69","author":"JH Haduong","year":"2022","unstructured":"Haduong JH, Heske CM, Allen-Rhoades W, et al. An update on rhabdomyosarcoma risk stratrification and the rationale for current and future Children\u2019s Oncology Group clinical trials. Pediatr Blood Cancer. 2022;69:e29511.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR69","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1200\/JCO.2007.14.7207","volume":"26","author":"O Oberlin","year":"2008","unstructured":"Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from the United States and European cooperative groups. J Clin Oncol. 2008;26:2384\u20139.","journal-title":"J Clin Oncol"},{"key":"1781_CR70","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/pbc.10441","volume":"42","author":"D Joshi","year":"2004","unstructured":"Joshi D, Anderson JR, Paidas C, et al. Age is an independent prognostic factor in rhabdomyosarcoma: Results of a pooled analysis from the United States and European cooperative groups. Pediatr Blood Cancer. 2004;42:64\u201373.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1200\/JCO.2014.55.6787","volume":"32","author":"DO Walterhouse","year":"2014","unstructured":"Walterhouse DO, Pappo AS, Meza JL, et al. Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients with Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Chidlren\u2019s Oncoloyg Group. J Clin Oncol. 2014;32:31.","journal-title":"J Clin Oncol"},{"key":"1781_CR72","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1200\/JCO.2018.77.9694","volume":"36","author":"DS Hawkins","year":"2018","unstructured":"Hawkins DS, Chi YY, Anderson JR, et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: A report from the Children\u2019s Oncology Group. J Clin Oncol. 2018;36:2770\u20137.","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"1781_CR73","doi-asserted-by":"publisher","first-page":"e30556","DOI":"10.1002\/pbc.30556","volume":"70","author":"S Oberoi","year":"2023","unstructured":"Oberoi S, Crane JN, Haduong JH, et al. Children\u2019s Oncology Group\u2019s 2023 blueprint for research: Soft tissue sarcomas. Pediatr Blood Cancer. 2023;70(Suppl 6):e30556.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR74","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/pbc.25837","volume":"63","author":"L Mascarenhas","year":"2016","unstructured":"Mascarenhas L, Felgenhauer JL, Bond MC, et al. Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval-compressed chemothepray in newly diagnosed patients with localized Ewing sarcoma: a report from the children\u2019s oncology group. Pediatr Blood Cancer. 2016;63:493\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR75","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/cncr.11550","volume":"98","author":"A Ferrari","year":"2003","unstructured":"Ferrari A, Dileo P, Casanova M, et al. Rhabdomyosarcoma in adults:A retrospective analysis of 171 patients treated at a single institution. Cancer. 2003;98:571\u201380.","journal-title":"Cancer"},{"key":"1781_CR76","doi-asserted-by":"publisher","first-page":"e29924","DOI":"10.1002\/pbc.29924","volume":"69","author":"KD Wyatt","year":"2022","unstructured":"Wyatt KD, Birz S, Dawkins DS, et al. Creating a data commons: The International Soft Tissue SaRcoma ConsorTium (INSTRuCT). Pediatr Blood Cancer. 2022;69:e29924.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR77","unstructured":"Ries LAG, Smith MA, Burney JG et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975\u20131995. Bethesda, MD, National Cancer Institute, SEER Program. NIH publication number 99-4649. 1999."},{"key":"1781_CR78","doi-asserted-by":"crossref","unstructured":"Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of Soft Tissue Tumors: new and perspectives. 2020.3;113(2):70\u201384.","DOI":"10.32074\/1591-951X-213"},{"key":"1781_CR79","doi-asserted-by":"crossref","unstructured":"Orbach D, Brennan B, Bisogno G et al. The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: An international prospective case series. Lance Child Adolesc Health. 2017;(1):284\u201392.","DOI":"10.1016\/S2352-4642(17)30045-7"},{"key":"1781_CR80","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.2012.46.0147","volume":"31","author":"P Lagarde","year":"2013","unstructured":"Lagarde P, Przybyl J, Brulard C, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013;31:608\u201315.","journal-title":"J Clin Oncol"},{"key":"1781_CR81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/his.14443","volume":"80","author":"JL Davis","year":"2022","unstructured":"Davis JL, Al-Ibraheemi A, Rudzinsky ER, et al. Mesenchymal neoplasms with NTRK and other kinase gene alterations. Histopathologi. 2022;80:4\u201318.","journal-title":"Histopathologi"},{"key":"1781_CR82","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch T, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. NEJM. 2018;378:731\u20139.","journal-title":"NEJM"},{"key":"1781_CR83","doi-asserted-by":"publisher","first-page":"28802","DOI":"10.1002\/cncr.30721","volume":"123","author":"D Callegaro","year":"2017","unstructured":"Callegaro D, Miceli R, Mariani L, et al. Soft tissue sarcoma nomograms and their incorporation into practice. Cancer. 2017;123:28802\u20132820.","journal-title":"Cancer"},{"key":"1781_CR84","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","volume":"17","author":"D Callegaro","year":"2016","unstructured":"Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localized soft-tissue sarcomas of the extremities: A retrospective analysis. Lancet Oncol. 2016;17:671\u201380.","journal-title":"Lancet Oncol"},{"key":"1781_CR85","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2022.03.028","volume":"169","author":"A Ferrari","year":"2022","unstructured":"Ferrari A, Orbach D, Sparber-Sauer M, et al. The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: A critical review from the International Soft Tissue SaRcoma ConsorTium. Eur J Cancer. 2022;169:10\u20139.","journal-title":"Eur J Cancer"},{"key":"1781_CR86","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1002\/cncr.24929","volume":"116","author":"JD Khoury","year":"2010","unstructured":"Khoury JD, Coffin CM, Spunt SL, et al. Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents: A comparison of parameters used for the Federation Nationale Ddes Centers de Lutte Contre le Cancer and Pediatric Oncology Group Systems. Cancer. 2010;116:2266\u201374.","journal-title":"Cancer"},{"key":"1781_CR87","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejca.2022.11.014","volume":"190","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, He J, Spunt SL, et al. Lymph node metastases in paediatric and young adult patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) Findings form Children\u2019s Oncology Group (COG) study ARST0332. Eur J Cancer. 2023;190:89\u201398.","journal-title":"Eur J Cancer"},{"key":"1781_CR88","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1002\/cncr.33189","volume":"126","author":"G Basile","year":"2020","unstructured":"Basile G, Mattei JC, Alshaygy I, et al. Curability of patients with lymph node metastases from extremity soft-tissue sarcoma. Cancer. 2020;126:5098\u2013108.","journal-title":"Cancer"},{"key":"1781_CR89","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(19)30672-2","volume":"21","author":"L Spunt Sl, Million","year":"2020","unstructured":"Spunt Sl, Million L, Chi YY, et al. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): A Childrens Oncology Group prospective study. Lancet Oncol. 2020;21:145\u201361.","journal-title":"Lancet Oncol"},{"key":"1781_CR90","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2011.37.7218","volume":"30","author":"A Gronchi","year":"2012","unstructured":"Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult sof tissue sarcoma: A randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30:850\u20136.","journal-title":"J Clin Oncol"},{"key":"1781_CR91","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.hoc.2005.03.001","volume":"19","author":"SM Schuetze","year":"2005","unstructured":"Schuetze SM. Imaging and response in soft tissue sarcomas. Hematol Oncol Clin North Am. 2005;19:471\u201387.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1781_CR92","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3390\/cancers14092078","volume":"14","author":"AE Eisenhardt","year":"2022","unstructured":"Eisenhardt AE, Brugger Z, Lausch U, et al. Genotyping of circulating free DNA enables monitoring of tumor dynamics in synovia sarcomas. Cancers (Basel). 2022;14:2078.","journal-title":"Cancers (Basel)"},{"key":"1781_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.07.002","volume":"143","author":"HJ Lim","year":"2019","unstructured":"Lim HJ, Johnny Ong CA, Tan JW, et al. Utility of positron emission tomography\/computed tomography (PET\/CT) imaging in the evaluation of sarcomas: A systematic review. Crit Rev Oncol Hematol. 2019;143:1\u201313.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1781_CR94","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jamaoncol.2023.0042","volume":"9","author":"D Wang","year":"2023","unstructured":"Wang D, Harris J, Kraybill WG, et al. Pathologic complete response and clinical outcomes in patients with localized soft tissue sarcoma treated with neoadjuvant chemoradiotherapy or radiotherapy: the NRG\/RTOG 9514 and 0630 nonrandomized clinical trials. JAMA Oncol. 2023;9:646\u201355.","journal-title":"JAMA Oncol"},{"key":"1781_CR95","doi-asserted-by":"crossref","unstructured":"Mascarenhas L, van Tilburg CM, Doz F et al. Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: an expanded dataset. Presented at ASCO Annual Meeting. June 2, 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.10030"},{"issue":"11","key":"1781_CR96","doi-asserted-by":"publisher","first-page":"e31257","DOI":"10.1002\/pbc.31257","volume":"71","author":"SF Polites","year":"2024","unstructured":"Polites SF, Rhee DS, Seitz G, et al. Contemporary surgical management of pediatric non-rhabdomyosarcoma soft tissue sarcoma. Pediatr Blood Cancer. 2024;71(11):e31257.","journal-title":"Pediatr Blood Cancer"},{"key":"1781_CR97","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/JCO.23.01275","volume":"42","author":"AR Weis","year":"2023","unstructured":"Weis AR, Harrison DJ. Soft tissue sarcomas in adolescents and young adults. J Clin Oncol. 2023;42:675\u201385.","journal-title":"J Clin Oncol"},{"key":"1781_CR98","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/SLA.0000000000000869","volume":"260","author":"MF Brennan","year":"2014","unstructured":"Brennan MF, Antonescu CR, Moraco N, et al. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260:416\u201322.","journal-title":"Ann Surg"},{"key":"1781_CR99","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1200\/JCO.2012.44.3747","volume":"31","author":"A Gronchi","year":"2013","unstructured":"Gronchi A, Miceli R, Shurell E, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma; Histology-specific overall survival and disease-free survival nomgrams built on major sarcoma center data. J Clin Oncol. 2013;31:1649\u201355.","journal-title":"J Clin Oncol"},{"key":"1781_CR100","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/jso.24112","volume":"113","author":"S Byerly","year":"2016","unstructured":"Byerly S, Chopra S, Nassif NA, et al. The role of margins in extremity soft tissue sarcoma. J Surg Oncol. 2016;113:333\u20138.","journal-title":"J Surg Oncol"},{"key":"1781_CR101","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13014-022-02106-2","volume":"17","author":"M Kobus","year":"2022","unstructured":"Kobus M, Roohani S, Ehret F, et al. The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma. Radiat Oncol. 2022;17:139.","journal-title":"Radiat Oncol"},{"key":"1781_CR102","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","volume":"18","author":"B Seddon","year":"2017","unstructured":"Seddon B, Straus SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDis): A randomized controlled phase 3 trial. Lancet Oncol. 2017;18:1397\u2013410.","journal-title":"Lancet Oncol"},{"key":"1781_CR103","first-page":"415","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first line treatment of advanced or metastatic soft tissue sarcoma: A randomized controlled phase 3 trial. Lacet Oncol. 2014;15:415\u201323.","journal-title":"Lacet Oncol"},{"key":"1781_CR104","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1200\/JCO.19.03289","volume":"38","author":"A Gronchi","year":"2020","unstructured":"Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcoma: Final resutls of randomized trials from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clinc Oncol. 2020;38:2178\u201386.","journal-title":"J Clinc Oncol"},{"key":"1781_CR105","doi-asserted-by":"crossref","unstructured":"D\u2019Angela SP, Melchiori L, Merchant MS et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259) T cells in synovial sarcoma. Cancer Disc. 2018; 944\u201357.","DOI":"10.1158\/2159-8290.CD-17-1417"},{"key":"1781_CR106","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1158\/1078-0432.CCR-21-2001","volume":"27","author":"MB Livingston","year":"2021","unstructured":"Livingston MB, Jagosky MH, Robinson MM, et al. Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma. Clin Cancer Res. 2021;27:6414\u201331.","journal-title":"Clin Cancer Res"},{"key":"1781_CR107","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1470-2045(20)30325-9","volume":"21","author":"AR Weiss","year":"2020","unstructured":"Weiss AR, Chen YL, Scharschmidt TJ, et al. Pathological response in children and adults with large urnesected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): A multicentre, randomised, open label-phase 2 trial. Lancet Oncol. 2020;21:1110\u201322.","journal-title":"Lancet Oncol"},{"key":"1781_CR108","doi-asserted-by":"publisher","first-page":"11719","DOI":"10.1002\/cam4.5671","volume":"12","author":"M Sparber-Sauer","year":"2023","unstructured":"Sparber-Sauer M, Ferrari A, Spunt SL, et al. The significance of margins in pediatric non-rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the International Soft Tissue SaRcoma ConsorTium (INStruCT). Cancer Med. 2023;12:11719\u201330.","journal-title":"Cancer Med"},{"key":"1781_CR109","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1200\/JCO.2014.60.0734","volume":"33","author":"SS Bielack","year":"2015","unstructured":"Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, doxorubicin, and cisplatin (map) plus maintenance pegylated interferon alfa-2b versus map alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative map: first results of the euramos-1 good response randomized controlled trial. J Clin Oncol. 2015;33:2279\u201387.","journal-title":"J Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01781-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01781-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01781-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:02:50Z","timestamp":1779271370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01781-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1781"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01781-8","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies with human subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"56"}}